Skip to main content

RESOURCES

15.09.2021 Press releases

MedImpact Receives PBMI Excellence Award for Quality Improvement

Industry group recognizes MedImpact’s novel pharmacogenomics solution.

ORLANDO, Fla., Sept. 15, 2021 — MedImpact today announced that it has received the 2021 Pharmacy Benefit Management Institute (PBMI) Excellence award for quality improvement for its novel pharmacogenomics (PGx) solution.

PGx is the study of how a person’s genetics affects their response to a drug. An individual’s genetic makeup can determine how effective a medication will be, requiring changes to dosing or different medications altogether. It can also determine the risk of experiencing an adverse event from a medication, such as stroke, arrhythmia, and cardiomyopathy. Although medical science has long understood the links between genes and drugs, the healthcare industry has struggled to use this information to deliver actionable results to prescribers.

“MedImpact’s solution will help members and prescribers identify the medications and dosages that are right for members the first time,” said Brian Haug, Executive Director of PBMI. “We granted this award because of MedImpact’s novel approach to pharmacogenomics and its potential to make a real difference for both members and health plans.”

FROM OUR LEADERS

“We are honored to receive this award and grateful for the difference this program is making for our members and clients.”

LISA CASHMAN MEDIMPACT VP OF SPECIALTY PROGRAMS

With MedImpact’s PGx solution, members provide their genetic information by mailing in a simple mouth swab test. MedImpact then provides a report to the member and their prescribers with test results. MedImpact also monitors the members’ pharmacy claims and notifies them and their prescribers of either potential adverse events or drugs that are likely to be ineffective. The list of drugs that the program monitors is continually revised and updated as more evidence is gathered, including drugs recently approved by the U.S. Food and Drug Administration.

The MedImpact approach is significantly different than other solutions on the market that conduct a single genetic test to see how an individual will respond to a single therapy prescribed by a single prescriber. MedImpact’s program screens for genetic interactions with more than 200 commonly prescribed medications and provides members and their prescribers with the information. This program is available to members of MedImpact clients which participate in the PGx program.

MedImpact accepted the award at the 26th PBMI Annual National Conference in Orlando.

 

 

 

SHARE
RESOURCES
Read on.
Keep up to date on the latest in the industry.
Press releases
MedImpact Receives Three-Year NCQA Reaccreditation
Reaffirms commitment to high quality standards and rigorous process assessment in Utilization Management
READ MORE
Press releases
Krista Kelley Named Senior Vice President, Sales and Marketing for MedImpact
Industry veteran to lead the effort by the largest independent PBM to deliver innovation, competition, and choice to government and commercial payers
READ MORE
Client news
MedImpact in American Health and Drug Benefits
Karen Geary explores how an individual’s genetic makeup can impact how they will react to certain medications, and how we can help make prescribing safer and more effective.
READ MORE

Ready for clarity from your PBM?